İmmün Aracılı Ataksiler

Pavone P, Praticò AD, Pavone V, et al. Ataxia in children: early recognition and clinical evaluation. Ital J Pediatr. 2017;43(1):6.

Mitoma H, Manto M, Hadjivassiliou M. Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms. J Mov Disord. 2021;14(1):10-28.

Brouwer B. Beitrag zur kenntnis der chronischen diffusen kleinhirnerkranghkungen. Neurol Centralbl.1919;38:674–682.

Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 1983;14:609–613.

Honnorat J, Saiz A, Giometto B,et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. Study of 14 patients. Arch Neurol. 2001;58:225–230.

Hadjivassiliou M, Grünewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological and neuropathological characteirstics of gluten ataxia. Lancet. 1998;352:1582–1585.

Zuliani L, Sabater L, Saiz A,et al. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology. 2007;68:239–240.

Jarius S, Martínez-García P, Hernandez AL, et al. Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation. 2013;10:7.

Mitoma H, Adhikari K, Aeschlimann D, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15:213–232.

Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14.

Mitoma H, Manto M, Hadjivassiliou M. Nonparaneoplastic autoimmune cerebellar ataxias. MedLink Neurology. 2019 Aug 23.

Hadjivassiliou M, Boscolo S, Tongiorgi E,et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord. 2008;23:1370–1377.

Hadjivassiliou M, Graus F, Honnorat J,et al. Diagnostic criteria for primary autoimmune cerebellar ataxia–guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias. Cerebellum. 2020;19:605–610.

Mitoma H, Manto M. The physiological basis of therapies for cerebellar ataxias. Ther Adv Neurol Disord. 2016;9:396–413.

Mitoma H, Manto M, Hampe CS. Time is cerebellum. Cerebellum. 2018;17:387–391.

Hadjivassiliou M, Mitoma H, Manto M. Autoimmune ataxia. In: Mitoma H, Manto M, editors. Neuroimmune Diseases: From Cells to the Living Brain. Cham, Switzerland: Springer Nature ve 599–620., 2019. pp.

Hadjivassiliou M, Graus F, Honnorat J,et al. Diagnostic criteria for primary autoimmune cerebellar ataxia–guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias. Cerebellum. 2020;19:605–610.

Ducray F, Demarquay G, Graus F, et al. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. Eur J Neurol. 2014;21:731–735.

Mitoma H, Adhikari K, Aeschlimann D, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15(2):213-232.

Muñiz-Castrillo S, Honnorat J. Mitoma H, Manto M. Neuroimmune Diseases: From Cells to the Living Brain. Cham, Switzerland: Springer Nature, syndromes, 2019. Paraneoplastic neurological ve 439–485., pp.

Jarius S, Wildemann B. ‘Medusa-head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: antimGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation. 2015;12:166.

Hampe CS. Significance of autoantibodies. In: Mitoma H, Manto M, editors. Neuroimmune Diseases: From Cells to the Living Brain. Cham, Switzerland: Springer Nature ve 109–142., 2019. pp.

Clin, Hadjivassiliou M. Immune-mediated acquired ataxias. Handb, 2012 ve 103:189–199.

Mitoma H, Manto M, Hadjivassiliou M. Nonparaneoplastic autoimmune cerebellar ataxias. MedLink Neurology. 2019 Aug 23.

Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14.

Sawaishi Y, Takada G. Acute cerebellitis. Cerebellum. 2002;1:223–228.

Ito H, Sayama S, Irie S,et al. Antineuronal antibodies in acute ataxia following Epstein-Barr infection. Neurology. 1994;44:1506–1507.

Blumkin L, Pranzatelli MR. Acquired ataxias, infectious and para-infectious. Handb Clin Neurol. 2012;103:137–146.

Sivaswamy L. Approach to acute ataxia in childhood: diagnosis and evaluation. Pediatr. 2014;43:153–159.

Connolly AM, Dodson WE, Prensky AL, Rust RS. Course and outcome of acute cerebellar ataxia. Ann Neurol. 1994;35:673–679.

Armangué T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016;73:417–424.

Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69:1598–1607.

Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–340.

Giometto B, Grisold W, Vitaliani R,et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67:330–335.

Graus F, Delattre JY, Antoine JC,et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140.

Shams’ili S, Grefkens J, de Leeuw B,et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003; 126:1409–1418.

Mitoma H, Manto M, Hampe CS. Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias. J Immunol Res. 2017;2913297.

Mitoma H, Manto M, Hadjivassiliou M. Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms. J Mov Disord. 2021;14(1):10-28.

Ariño H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014; 71:1009–1016.

Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol. 2004;61(6):902-904.

Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders - new insights. Curr Opin Neurol. 2016;29:496–506.

Ishida K, Mitoma H, Song SY, et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol. 1999;46:263–267.

Hampe CS, Petrosini L, De Bartolo P, et al. Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet J Rare Dis. 2013;10.1186/, 8:82.

Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges. Curr Neuropharmacol. 2019;17:33–58.

Hadjivassiliou M. Advances in Therapies of Cerebellar Disorders: Immune-mediated Ataxias. CNS Neurol Disord Drug Targets. 2019;18(6):423-431.

Hadjivassiliou M, Currie S, Hoggard N. MR spectroscopy in paraneoplastic cerebellar degeneration. J Neuroradiol. 2013;40:310–312.

Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grünewald RA. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74(9):1221-1224.

Souayah N, Chin RL, Brannagan TH,et al. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol. 2008;15:1300–1303.

Hadjivassiliou M, Aeschlimann P, Sanders DS, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology. 2013;80:1740–1745.

Cervio E, Volta U, Verri M,et al. Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro. Gastroenterology. 2007;133:195–206.

Hadjivassiliou M, Grünewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry. 2002;72:560–563.

Hadjivassiliou M, Sanders DS, Woodroofe N, Williamson C, Grünewald RA. Gluten ataxia. Cerebellum. 2008;7:494–498.

Hadjivassiliou M, Grünewald RA, Sanders DS, Shanmugarajah P, Hoggard N. Effect of gluten-free diet on cerebellar MR spectroscopy in gluten ataxia. Neurology. 2017; 89:705–709.

Sarrigiannis PG, Hoggard N, Aeschlimann D,et al. Myoclonus ataxia and refractory coeliac disease. Cerebellum Ataxias. 2014;1:11.

Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve. 2005;31:157–174.

Mori M, Kuwabara S, Fukutake T,et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104–1106.

Urushitani M, Udaka F, Kameyama M. Miller Fisher-Guillain-Barré overlap syndrome with enhancing lesions in the spinocerebellar tracts. J Neurol Neurosurg Psychiatry. 1995;58:241–243.

Sandler RD, Hoggard N, Hadjivassiliou M. Miller-Fisher syndrome: is the ataxia central or peripheral? Cerebellum Ataxias. 2015 ve 2:3.

Kim YK, Kim JS, Jeong SH, et al. Cerebral glucose metabolism in Fisher syndrome. J Neurol Neurosurg Psychiatry. 2009;80:512–517.

Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013 ve 73:120–128.

Tobin WO, Lennon VA, Komorowski L,et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–1803.

Van Sonderen A, Ariño H, Petit-Pedrol M,et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87:521–528.

Joubert B, Gobert F, Thomas L,et al. Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4:e371.

DeBellard ME, Tang S, Mukhopadhyay G,et al. Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein. Mol Cell Neurosci. 1996;7:89–101.

Zis P, Rao DG, Hoggard N,et al. Anti-MAG associated cerebellar ataxia and response to rituximab. J Neurol. 2018;265:115–118.

Pittock SJ, Debruyne J, Krecke KN, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) Brain. 2010;133:2626–2634.

Dudesek A, Rimmele F, Tesar S, et al. CLIPPERS: Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders.Clin Exp Immunol. 2014; 175:385–396.